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Abstract There is increasing evidence that inﬂammation
plays an important role in the progression of acute ischemic
stroke (AIS). The primary aims of this study were to
examine the serum levels of 13 cytokines, C-reactive
protein (CRP), glucose, and hemoglobin in AIS patients,
and their relationship to stroke lateralization, type, and
infarct volume. Forty-ﬁve patients with AIS were evalu-
ated. Blood samples were taken within 72 h, and volu-
metric analyses performed within 1–7 days after AIS onset.
Cytokines were measured in serum from all patients and
from 40 control subjects using Luminex Bio-Plex XMap
technology. The levels of interleukin (IL)-1ra (p\0.001),
IL-6 (p\0.001), IL-8 (p\0.001), IL-9 (p = 0.038), IL-
10 (p = 0.001), IL-12 (p = 0.001), IL-18 (p\0.001), and
GRO-a (CXCL1) (p = 0.017) were signiﬁcantly higher in
the AIS patients than in the controls. The IL-8 level was
signiﬁcantly correlated with age in the patient group
(r = 0.52, p\0.001). None of the variables were found to
be associated with stroke lateralization. Infarct volume was
signiﬁcantly positively correlated with CRP level
(r = 0.47, p = 0.005). Patients with radiologically con-
ﬁrmed infarctions had signiﬁcantly elevated serum levels
of GRO-a (p = 0.023). The cytokine proﬁle of the AIS
patients supports not only earlier ﬁndings of a proinﬂam-
matory response but also early activation of endogenous
immunosuppressive mechanisms. Novel ﬁndings of this
study are elevated serum levels of IL-9 and GRO-a. Ele-
vated GRO-a in AIS patients with radiologically conﬁrmed
infarctions suggests that GRO-a is speciﬁc for stroke of
known etiology. Our results indicate that CRP plays an
important role in the progression of cerebral tissue injury.
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Background
There is increasing evidence that inﬂammation plays an
important role in acute ischemic stroke (AIS), indicating
important interactions between the nervous and immune
systems [1]. Cerebral ischemia induces a robust inﬂam-
matory reaction that involves several cell types. Many
recent studies have focused on the inﬂammatory reaction
after the ischemic episode, identifying the roles of impor-
tant inﬂammatory signaling molecules, particularly cyto-
kines [2]. Cytokines are up-regulated in the brain after
stroke, and are expressed not only in immunological cells
but also in glial cells and neurons [3].
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DOI 10.1007/s00415-011-6006-0The most studied cytokines related to stroke are interleu-
kin (IL)-1b, IL-6, IL-10, and tumor necrosis factor-a (TNF-
a). The proinﬂammatory cytokines TNF-a, IL-1b, and IL-6
aresecretedintheischemicregionbyactivatedimmunecells,
which drive the inﬂammatory process and accelerate addi-
tional inﬂammatory processes by inducing the expression of
inﬂammatory molecules. These molecules recruit more cir-
culating leukocytes, which inﬁltrate the ischemic region and
leadto further loss of neuronal cells and brain tissue, thereby
possibly enlarging the cerebral infarct area [4, 5]. Whether
postischemic inﬂammatory responses are deleterious or
beneﬁcialtobrainrecoveryispresentlyamatterofdebate[6].
Several studies have examined whether the inﬂammatory
response following AIS is related to infarct volume [7–14]
andstrokesubtype[15].Theresultsareinconsistent,thus the
roles of the cytokines involved are still unclear.
Various known cytokines have been studied individu-
ally, but no study has evaluated numerous different cyto-
kines in a single patient group using one methodology. The
aim of this study was to measure the serum levels of 13
cytokines in patients with AIS to improve the under-
standing of the complex interplay between the pro- and
anti-inﬂammatory cytokines involved. We also examined
the relation of serum levels of hemoglobin, C-reactive
protein (CRP), and glucose to stroke lateralization, diag-
nostic subtype, and infarct volume.
Methods
Patients
The cohort comprised 45 patients included in a longitudinal
study of ﬁrst-ever stroke patients admitted to Buskerud
Hospital, a regional hospital in Norway. The recruiting
procedure is described in detail elsewhere [16]. In short, the
inclusion criteria were clinical presentation of ﬁrst-ever
stroke, age 18 years or older, and exhibiting sufﬁcient cog-
nitive functioning to participate. Stroke was deﬁned as the
presence of rapidly developing focal neurological signs or
symptoms of vascular origin that persisted for[24 h. The
exclusion criteria were no serum samples collected, uncer-
tain diagnosis of AIS, presence of cancer, receiving throm-
bolysis therapy, and uncertain symptom onset.
Clinical and instrumental evaluation
A general medical history was collected, and physical and
neurological examinations, standard laboratory tests,
12-leadECG,andcerebralCTwereperformedinallpatients
onadmission.Patients withoutclearradiologicalﬁndingson
admission, but with persistent clinical symptoms indicative
of AIS after 2–4 days were submitted to a secondary CT or
MRI scan. The type of AIS was classiﬁed according to the
Trial of Org 10172 in Acute Stroke Treatment (TOAST)
classiﬁcation [17]: cardioembolic infarct (CEI), large-artery
atherosclerosis (LAAS), lacunar infarct (LAC), stroke of
undetermined etiology (UDE), and stroke of other deter-
mined etiology. Lateralization of the stroke was determined
byclinicalﬁndingsandimagingresults,oronaclinicalbasis
only in patients without conclusive CT or MRI ﬁndings.
Location of the stroke, supra- or infratentorial respectively,
was determined by radiological ﬁndings.
The functional disability of patients in the acute phase
was measured using the Barthel Index-20 scale (BI-20)
[18]. The BI-20 has proven to be the most reliable dis-
ability scale for stroke; it correlates strongly with the
immediate poststroke condition [19].
Imaging and volumetric analysis
The imaging used for measurement of infarct volume was
performedwithin1–2 days,3–5 days,and7 daysafterstroke
onset for 11, 22, and one of the 34 patients, respectively.
InfarctvolumesweremeasuredoneitherMRI(24/34cases)or
CT (10/34). On MRI, diffusion sequences were used in the
axialplane,combinedwithsagittalT2turbospin-echoand/or
coronal ﬂuid-attenuated inversion recovery imaging. An on-
screen measuring technique was used. On CT, measurements
weremadeonaxialslicesincombinationwiththicknessdata.
Control subjects
Control serum samples were prepared by collecting blood
from 40 healthy donors (The Bloodbank, Oslo University
Hospital, Ulleva ˚l, Oslo, Norway) with an even female/male
distribution. We achieved a biobank similar to that of the
material collected from our stroke patients by selecting
donors aged 50–70 years. None of the donors were using
immunosuppressive medication.
Blood collection and serum preparation
Blood samples were taken at the same time point for all
blood components measured; at\24, 24–48, and 48–72 h
after stroke onset in 35, 7, and three of the 45 patients,
respectively. For cytokine measurements blood was col-
lected in 7.5-ml serum S-Monovette gel tubes (Sarstedt,
Nu ¨mbrecht, Germany), and stored for 30–120 min at room
temperature prior to centrifugation at 1,4009g for 12 min.
Serum samples were frozen at -70C.
CRP, glucose, and hemoglobin measurements
Serum levels of CRP, glucose, and hemoglobin were all
determined with clinically validated assays. Determination
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123of CRP was performed using a standard latex immunoas-
say; CRP Vario (Abbott Diagnostics). Glucose was deter-
mined using Architect cSystems (Abbott Diagnostics).
Finally, Hemoglobin was determined using Advia 120
Hematology system (Siemens Health Care Diagnostics).
Cytokine measurement
Cytokine levels were measured using a Luminex IS 100
instrument (Bio-Rad, Hercules, CA). Based on a screening
of representative serum samples using the Bio-Plex human
cytokine 27-plex assay (catalog no. 171A11127, Bio-Rad),
the following custom plex was purchased to screen all
samples: Bio-Plex Pro
TM Human Cytokine Group I; IL-1b,
IL-1ra, IL-2, IL-4, IL-6, IL-8, IL-9, IL-10, IL-12, TNF-a,
and interferon-c (IFN-c); Bio-Plex Pro
TM Human Cytokine
Group II; and GRO-a (CXCL1) and IL-18 (Bio-Rad). All
samples were thawed on ice, vortexed, spun down at
14,0009g for 10 min at 4C, and then diluted at 1:4.
Longitudinal controls were used to assess the interassay
variation. The coefﬁcient of variation for controls ranged
from 9 to 19% on the exponential phase of the standard
curve.
Statistical analysis
The two-tailed Mann–Whitney test was used to compare
the median values of cytokine variables in two groups. The
independent-samples t test was used to compare means.
The level of statistical signiﬁcance was set at p\0.05. If
more than 50% of the values of a cytokine variable were
not detectable in at least one of the groups, the variable was
dichotomized as detectable (yes/no) and analyzed using
Pearson’s Chi-square test.
Since the distributions of most of the cytokine variables
were markedly skewed, the results are presented as medi-
ans and interquartile ranges. When age was found to be a
confounder for a difference in cytokine variables between
the groups, linear regression analysis was used to adjust for
age. The Spearman correlation coefﬁcient was used to
quantify the association between two continuous variables.
All statistical analyses were performed using the SPSS
statistical package (version 15, SPSS, Chicago, IL).
Results
All clinical data of the AIS patients are presented in
Table 1. The gender distribution did not differ signiﬁcantly
between the AIS and control groups, but the mean age was
signiﬁcantly higher in the former (67.7 vs. 59.1 years,
respectively; p\0.001). Twenty-two patients had right-
sided, 21 left-sided and 2 bilateral ischemic stroke. The
infarct volume measured in the 34 patients with a radio-
logically conﬁrmed infarction ranged from 0.5 to 140 cm
3,
with a median value of 2 cm
3 (1, 17).
Serum levels of cytokines in the AIS and control sub-
jects are also presented in Table 1. The levels of the fol-
lowing cytokines were signiﬁcantly higher in the AIS
patients than in the controls: IL-1ra (p\0.001), IL-6
(p\0.001), IL-8 (p\0.001), IL-9 (p = 0.038), IL-10
(p = 0.001), IL-12 (p = 0.001), IL-18 (p\0.001), and
GRO-a (p = 0.017). IL-8 was signiﬁcantly correlated with
age in the patient group (r = 0.52, p\0.001), but not in
the control group. The difference in IL-8 between the
groups remained signiﬁcant after adjusting for age
(p\0.001).
To get an indication of the stability of the cytokines,
secondary blood samples were taken from 33 of the
patients, between 2 and 5 days after stroke onset. Com-
paring the acute-phase cytokine levels and these secondary
cytokine levels revealed that the only cytokines that
changed signiﬁcantly were IL-18 and GRO-a. The median
level of IL-18 decreased from 1,820 to 1,630 lg/ml
(p = 0.011), whilst that of GRO-a decreased from 1,207 to
868 lg/ml (p = 0.006). This indicates that most of the
investigated cytokines are relatively stable for many hours,
or even days, after stroke onset. This is also supported by
several previous studies, as discussed later.
The BI-20 score was signiﬁcantly negatively correlated
with the levels of IL-2 (r = –0.354, p = 0.02), IL-6 (r =
–0.334, p = 0.028), IL-12 (r = 0.38, p = –0.012), and
IFN-c (r = –0.37, p = 0.014). No differences were found
between left-sided and right-sided infractions for any of the
immunological markers, hemoglobin, glucose, or BI-20
score. The group with infratentorial ﬁndings was too small
(n = 4) to allow for detailed statistical analysis on location.
Infarct volume was signiﬁcantly positively correlated
with CRP level (r = 0.47, p = 0.005). No correlation was
found between infarct volume and any of the immuno-
logical markers, hemoglobin, glucose, or BI-20 score.
TOAST variables were dichotomized in radiologically
conﬁrmed infarctions (merged CEI, LAAS, and LAC) and
radiologically unconﬁrmed infarctions (UDE); data pre-
sented in Table 2. Patients with radiologically conﬁrmed
infarctions had signiﬁcantly elevated serum levels of GRO-
a (1,613 vs. 888 lg/ml,p= 0.023). This group also had
signiﬁcantly lower age (56 vs. 74 years, p = 0.037) and
signiﬁcantly lower prevalence of coronary disease (9 vs.
36%), p = 0.028). Age and presence of coronary disease
was not correlated with GRO-a; thus, the differences in
serum level of GRO-a cannot be explained by the differ-
ence in these variables between the two groups. We did not
ﬁnd any differences between these two groups in regard to
any of the other immunological markers, hemoglobin,
glucose, or BI-20 score.
J Neurol (2011) 258:677–685 679
123Table 1 Clinical variables of the acute ischemic stroke (AIS) patients and cytokine serum levels of these and control subjects
Characteristic Stroke patients (n = 45) Control subject (n = 40) p
Male, n (%) 27 (60) 20 (50) 0.14
Mean age, years ± SD
e 67.7 ± 11.8 59.1 ± 5.7 <0.001
Right-sided ischemic stroke, n (%) 22 (49%)
Radiologically conﬁrmed infarction, n (%) 34 (53%)
Supratentorial infarction, n (% of 34) 30 (88%)
TOAST
CEI 5 (11%)
LAAS 10 (22%)
LAAC 19 (42%)
UDE 11 (24%)
Medication
Prednisolone 3 (7%)
NSAIDs 3 (7%)
Co-morbidity
Hypertension 28 (62%)
Atrial ﬁbrillation 6 (13%)
Coronary disease 7 (16%)
Diabetes 4 (9%)
Rheumatism 2 (4%)
Psoriatic arthritis 3 (7%)
Bechterew’s disease 1
Hyperthyroidism 1
Mean values, ±SD
Hemoglobin (g/dl) 14.3 ± 1.3
Glucose (mmol/l) 7.0 ± 2.3
a
Median values, interquartile range
BI-20 20 (17, 20)
b
Infarct volume (cm
3) 2 (1, 17)
CRP (mg/l) 3 (2.0, 6.5)
Median values, interquartile range
c
Cytokines
IL-1 ra (lg/ml) 1,170 (840, 1,573) 492 (386, 662) <0.001
IL-8 (lg/ml) 200 (123, 251) 98 (73, 130) <0.001
IL-18 (lg/ml) 1,767 (1,405, 2,262) 1,187 (899, 1,689) <0.001
GRO-a 1,493 (431, 1,821) 691 (483, 1,351) 0.017
Dichotomized values (% detectable of total)
d
Cytokines
IL-1b 10 (22%) 8 (20%) 0.80
IL-2 2 (4%) 1 (3%) 0.63
IL-4 9 (22%) 4 (10%) 0.19
IL-6 42 (93%) 15 (38%) <0.001
IL-9 18 (41%) 8 (20%) 0.038
IL-10 24 (56%) 8 (21%) 0.001
IL-12 24 (57%) 9 (23%) 0.001
IFN-c 12 (27%) 8 (20%) 0.47
TNF-a 27 (60%) 18 (45%) 0.17
Signiﬁcant ﬁndings (p\0.05) are marked with bold-faced types
a One missing case
b Two missing cases
c Two-tailed Mann–Whitney test was used for comparison of the groups
d Pearson Chi-square test was used for comparison of the groups
e Independent sample t-test was used for comparison of the groups
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123Table 2 Clinical variables and serum levels of cytokine in patients with and without radiologically conﬁrmed infarctions
Variable Patients with radiologically
conﬁrmed infarctions (merged
CEI, LAAS and LAC) (n = 34)
Patients without radiologically
conﬁrmed infarctions
(UDE) (n = 11)
p
Male, n (%) 20 (74) 7 (64)
Mean age, years ± SD
c 65 ± 12.2 74.1 ± 8.1 0.037
Right-sided ischemic stroke, n (%) 16 (47%) 6 (55%) 0.34
Medication
Prednisolone 2 (6%) 1 (9%)
NSAIDs 3 (9%) None
Co-morbidity
Hypertension 21 (62%) 7 (63%) 0.91
Atrial ﬁbrillation 5 (15%) 1 (9%) 0.63
Coronary disease 3 (9%) 4 (36%) 0.028
Diabetes 2 (6%) 2 (18%) 0.21
Rheumatism 2 (6%) None 0.41
Psoriatic arthritis 1 (3%) 2 (18%) 0.14
Bechterew’s disease 1 (3%) None 0.57
Hyperthyroidism None 1 (9%) 0.24
Mean values, ±SD
c
Hemoglobin (g/dl) 14.3 ± 1.2 14.3 ± 1.6 0.96
Glucose (mmol/l) 6.8 ± 2.3 7.7 ± 2.4
a 0.29
Median values, interquartile range
d
BI-20 20 (19, 20)
b 18 (16, 20) 0.06
Infarct volume (cm
3) 2 (1, 16.8) – –
CRP (mg/l) 2.5 (2.0, 6.3) 4.0 (2.0, 7.0) 0.99
Median values, interquartile range
d
Cytokines
IL-1 ra (lg/ml) 1,206 (917, 1,618) 843 (718, 1,561) 0.26
IL-8 (lg/ml) 192 (122, 228) 267 (123, 367) 0.11
IL-18 (lg/ml) 1,807 (1,474, 2,255) 1,649 (1,227, 2,290) 0.49
GRO-a 1,613 (520, 2,192) 888 (0, 1,214) 0.023
Dichotomized values
e (% detectable of total)
Cytokines
IL-1b 8 (24%) 2 (18%) 0.83
IL-2 1 (3%) 1 (9%) 0.79
IL-4 8 (24%) 1 (10%) 0.65
IL-6 31 (91%) 11 (100%) 0.09
IL-9 16 (47%) 2 (20%) 0.30
IL-10 18 (53%) 6 (55%) 0.65
IL-12 20 (59%) 7 (64%) 0.78
IFN-c 8 (24%) 4 (36%) 0.56
TNF-a 20 (59%) 7 (64%) 0.81
Signiﬁcant ﬁndings (p\0.05) are marked with bold-faced types
a One missing case
b Two missing cases
c The independent sample t-test was used to compare means
d The two-tailed Mann–Whitney test was used to compare median values
e The two-tailed Mann–Whitney test was used to compare median values for the continuously values
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Our ﬁnding of signiﬁcantly elevated circulatory IL-6 in the
AIS patients is consistent with the ﬁndings of numerous
previous studies [7–10, 20–25]. Although IL-6 is predom-
inantly viewed as a proinﬂammatory cytokine, it has been
suggested that it has two roles in cerebral ischemia: (1) as
an inﬂammatory mediator during the acute phase and (2) as
a neurotrophic mediator between the subacute and pro-
longed phases [26].
TNF-a and IL-1b were not elevated in the AIS group,
which is in accordance with two previous studies [7, 27],
but conﬂicts with others [15, 23, 28]. Based on the ﬁndings
that TNF-a and IL-1b are detectable as early as 1 h after
the onset of ischemia [26], and IL-6 is up-regulated by IL-
1b and TNF-a [29], it is reasonable to assume that the
levels of TNF-a and IL-1b had already peaked when we
made our measurements. Our ﬁndings of elevated levels of
IL-6 and IL-1ra, but not of TNF-a and IL-b, support earlier
ﬁndings that IL-6 suppresses the effects of TNF-a and IL-
1b both by inhibiting their production and by stimulating
the production of their respective circulating antagonists:
soluble TNF-a receptor and IL-1 receptor antagonist [30,
31]. Previous studies have also found elevated IL-1ra levels
in stroke patients [20, 27]. Consistent with our ﬁndings,
Beamer and coworkers found that both IL-1ra and IL-6
levels are elevated in stroke patients [32].
We found only one previous study of circulating IL-12
in AIS patients [33]. Consistent with our study, they found
an early increase in IL-12 serum level. Our ﬁnding of
signiﬁcantly elevated IL-18 levels in the AIS group is
supported by two previous studies [34, 35]. These results
suggest that both IL-12 and IL-18 are involved in stroke-
induced inﬂammation. Serum levels of IFN-c were not
elevated in the AIS group. We have not found any previous
studies on circulating IFN-c in AIS patients.
Studies of IL-8 in AIS patients are also scarce. In
accordance with the present study, two other studies found
a signiﬁcant elevation of plasma IL-8 in AIS patients [36,
37], while another study did not [38]. We found a signiﬁ-
cant correlation between serum IL-8 and age in the patient
group. The difference in IL-8 between the groups remained
signiﬁcant after adjusting for age (p\0.001). This indi-
cates that IL-8 may be a more prominent cytokine in older
patients. It is interesting to ask whether IL-8 may con-
tribute to that older age predicts poorer functional outcome
[39, 40] and mortality [41] after stroke. More studies are
needed to verify the role of IL-8 in older stroke patients.
We found that levels of GRO-a (also known as CXCL1),
a proinﬂammatory chemokine similar to IL-8, were sig-
niﬁcantly elevated in the AIS group. We were unable to
ﬁnd any other study measuring circulating GRO-a in AIS
patients; however, elevated cerebrospinal ﬂuid levels of
this cytokine in AIS patients have been noted [42]. The
ability of GRO-a to interact with other cytokines and
adhesion molecules expressed after stroke so as to poten-
tially promote leukocyte migration into the ischemic brain
has been thoroughly reviewed [42].
We found a signiﬁcant elevation in IL-9 in the AIS
group. To the best of our knowledge, our study is the ﬁrst
to have measured IL-9 in AIS patients, thus the role for IL-
9 in the progression of AIS is unclear. However, it has been
shown that the IL-9/IL-9 receptor signaling pathway rep-
resents a novel endogenous antiapoptotic mechanism for
cortical neurons [43]. It may therefore be hypothesized that
IL-9 may protect against stress-induced neuronal damage.
IL-10, but not IL-4, was signiﬁcantly elevated in the AIS
patients. One previous study supports our ﬁndings regard-
ing IL-4 [44]. A signiﬁcant decrease in IL-10 concentration
at 24 h followed by signiﬁcant increases at 72 and 144 h
has recently been found [45]. Elevated levels of the anti-
inﬂammatory cytokines IL-10 and IL-1ra suggest early
activation of endogenous immunosuppressive mechanisms
after stroke.
There have been large variations between similar studies
exploring relevant confounding factors such as medication
and comorbidities. To study a broader, more typical stroke
population, we chose not to exclude patients who were
using anti-inﬂammatory drugs, or those having any
comorbidity, except for cancer. The signiﬁcant differences
between the groups remained signiﬁcant (except for IL-9)
after adjusting for the medication or comorbidity (except
for hypertension) present in 20 patients (data not shown).
Hypertension was not excluded, because if we did, only 11
patients remained in the stroke group, which is too low of a
number for an appropriate statistical analysis.
No association was found between any of the studied
variables and stroke lateralization in our study. Relevant
research on whether the site of the lesion plays a role in
regulating alterations in the immune response in stroke is
limited. To the best of our knowledge, no other studies
have related stroke laterality to serum levels of cytokines in
AIS patients.
We found that infarct volume was signiﬁcantly posi-
tively correlated with CRP levels (r = 0.47, p = 0.005).
This is expected to be of clinical relevance, as a consid-
erable difference in median volume score was found
between patients with CRP above and below the median
CRP value (2.5 g/l); 11 vs. 1 cm
3, respectively. The ﬁnd-
ings of previous studies on the correlation between CRP
and cerebral infarct volume are conﬂicting; two are in
accordance with our ﬁndings [11, 38], one failed to ﬁnd a
correlation [24], and one found a higher plasma CRP only
for patients with larger infarcts [46]. We did not ﬁnd any
correlations between infarct volume and the levels of
cytokines. Previous studies have produced conﬂicting
682 J Neurol (2011) 258:677–685
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Several have shown positive correlations between infarct
volume and IL-6 level in serum or plasma [7, 9–11], while
Sotgiu and coworkers found serum IL-6 levels to be sig-
niﬁcantly negatively correlated with infarct volume [14],
and two other studies found no association between serum
IL-6 concentration and infarct volume [8, 21].
The release of inﬂammatory markers and lesion pro-
gression after a stroke are time dependent. The differences
between the aforementioned studies may be attributable to
large variations in timings of blood sampling and mea-
surements of infarct volume. We used a wide time window
for both. There are large variations between the afore-
mentioned studies regarding the timings of blood sampling
and volumetric measurements, and reasonable explanations
for the divergent ﬁndings cannot be found. Our ﬁnding that
CRP was signiﬁcantly positively correlated with infarct
volume, whereas the IL-6 was not, may reﬂect that IL-6 is
more sensitive to measurement timing. More studies are
needed, and in particular those designed to elucidate the
release of inﬂammatory markers in AIS and their role in the
progression of cerebral tissue injury. One aim of such
studies should be to clarify whether a reduction in some
central inﬂammatory markers could be beneﬁcial to stroke
patients.
Another aspect of blood samples timing is the question
of the stability of cytokines in blood. In our study, for 35 of
the 45 patients, blood samples were taken within 24 h after
stroke onset (T24), 7 were taken 24–48 h (T24–48) after
stroke onset and ﬁnally, 3 were taken between 48 and 72 h
(T48–72) after stroke onset. The T24–48 (n = 7) and T48–72
(n = 3) groups were considered too small to allow for
detailed statistical analysis. However, we found the same
signiﬁcant differences between the stroke patients and
controls analyzing the T24 sample alone, the T24 ? T24–48
sample, and ﬁnally, as presented in the paper, the
T24 ? T24–48 ? T48–72 sample. Thus signiﬁcant elevated
cytokine levels were found, in accordance with earlier
studies as discussed above, also in this ‘‘time-broad-sam-
ple’’. This indicates that elevated cytokine levels may last
longer than earlier supposed. This is supported by several
studies; serum levels of IL-6 has been found elevated until
90 days after the stroke [8, 10, 21], and IL-8 has been
found elevated in plasma during the ﬁrst week after
ischemic stroke [47]. In our opinion, our results are
strengthened by the fact that including these late samples
did not affect the signiﬁcant ﬁnding.
It is furthermore likely that the distribution of stroke
subtypes inﬂuences the differential ﬁndings discussed. For
CRP, this is supported by the ﬁnding of higher plasma CRP
only in patients with larger infarcts [46]. Regarding IL-6,
CEI subtype has been found to exhibit signiﬁcantly higher
plasma levels of IL-6 (and TNF-a and IL1-b), whereas
LAC subtype exhibited signiﬁcantly lower plasma levels of
these cytokines [15]. In our study, the numbers of patients
in the different subtype groups were low, and the distri-
bution was skewed. Some of the TOAST groups were too
small to allow for more detailed statistical analysis, which
is also a limitation of our study. However, we did ﬁnd that
the serum level of GRO-a was signiﬁcantly higher in
patients with radiologically conﬁrmed infarctions (pooled
subtypes CEI, LAAS, and LAC) than in patients without
(subtype UDE), where the latter had nearly normal levels
of GRO-a. These ﬁndings are novel and may indicate that
GRO-a may be the only cytokine measured that is speciﬁc
for strokes of known etiology. This aspect of GRO-a is
interesting and should be studied further in aim to
accomplish more knowledge about the pathophysiological
mechanisms in stroke of known etiology distinct to cryp-
togenic stroke.
The mean age was signiﬁcantly higher in the group of
patients without radiologically conﬁrmed infarctions as
compared to those with (74 vs. 56 years, p = 0.037). A
higher age among patients with UDE was also noted in a
population-based study on 531 stroke patients [48].
Another limitation of this study is that stroke severity
was not measured by using i.e., National Institutes of
Health Stroke Scale (NIHSS) or the Scandinavian Stroke
Scale. The BI-20 score was measured in the acute phase to
assess early functional disability, and was found to be
signiﬁcantly negatively correlated with levels of IL-2, IL-6,
IL-12, and IFN-c. An association between IL-6 and IL-12
and acute clinical outcome has also been noted by others,
using the NIHSS [25, 49] and the BI-20 [33], respectively.
Conclusions
This is the ﬁrst study to examine the serum levels of 13
cytokines in a single AIS population using one methodol-
ogy; eight were found to be elevated. The ﬁndings of
elevated levels of IL-9 and GRO-a in AIS patients are
novel. Our study supports the assertion that inﬂammatory
signaling molecules are of importance in AIS; an associa-
tion, assumed to be of clinical relevance, was found
between infarct volume and CRP level. Patients with
radiologically conﬁrmed infarctions had signiﬁcantly ele-
vated GRO-a, indicating that this cytokine may be the only
one speciﬁc for strokes of known etiology.
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